Levetiracetam versus Oxcarbazepine as monotherapy in newly diagnosed focal epilepsy: A systematic review and meta-analysis.

Sanjeev KharelRajeev OjhaSurendra Khanal

Published in: Brain and behavior (2022)

LEV is noninferior to OXC in terms of seizure freedom at week 24 and treatment withdrawal rate due to AEs among adults but long-term treatment data is still missing. Future multicentric double-blinded RCTs and real-world studies are of great need.

Keyphrases

newly diagnosed
clinical trial
electronic health record
deep learning
replacement therapy
study protocol
double blind